# Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Source: https://onco.cc/trials/nct04683250/  
OnCo record `nct04683250` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TAS0953/HM06 in non-small-cell lung cancer, run by Taiho Pharmaceutical Co., Ltd., now recruiting.

## Summary

Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities is a phase 1/2 interventional study registered as NCT04683250 by Taiho Pharmaceutical Co., Ltd., with 244 participants planned, started 2020-12-16 and due to reach its primary completion in 2030-03. Interventions recorded: TAS0953/HM06.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04683250
- Phase: 1/2
- Setting: Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
- Sponsor: Taiho Pharmaceutical Co., Ltd.
- Enrolled: 244

## Sources

- ClinicalTrials.gov NCT04683250: https://clinicaltrials.gov/study/NCT04683250

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Araris Biotech (Taiho)](https://onco.cc/companies/araris/)

---
JSON: https://onco.cc/api/v1/entities/nct04683250.json